Noga Therapeutics is a blood stem cell reprogramming gene therapy company that creates life-changing treatments for patients with severe and chronic illnesses.The company leverage the well-established lentiviral vector-based gene therapy technology, for blood stem cell reprogramming, to induce the production of missing proteins in the right cells at the right time.

Noga is developing DopaGene, a novel gene-therapy-based solution for direct dopamine production in the brain.

In a single, non-invasive procedure, Parkinson’s disease patient’s own blood stem cells are engineered with DopaGene and then re-infused into the bloodstream.

Macrophages that develop from the engineered stem cells migrate to the brain, where they settle and produce safe and effective levels of dopamine for years to come.

Local dopamine production eliminates the harsh side-effects of dopamine replacement-based products.